Lercanidipine "Approvable"; COHORT Shows Edema Advantage Over Norvasc
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Forest is highlighting a lower rate of edema as a potential tolerability advantage for its antihypertensive lercanidipine, based on results from the European COHORT trial.